Renal sympathetic denervation for the treatment of refractory hypertension

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 349-365

  Leong, Kui Toh Gerard ^a   Walton, Antony ^b   Krum, Henry ^c  

^a CHANGI GENERAL HOSPITAL   (Singapore)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Heart failure; Renal disease; Renal sympathetic denervation; Resistant hypertension; Sympathetic nervous system

Indexed keywords

ADRENERGIC SYSTEM; APNEA; FOLLOW UP; HEART FAILURE; HUMAN; INSULIN RESISTANCE; KIDNEY DENERVATION; KIDNEY DISEASE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; RADIOFREQUENCY; RENAL SYMPATHETIC DENERVATION; RESISTANT HYPERTENSION; REVIEW; SYMPATHECTOMY;

CATHETER ABLATION; DRUG RESISTANCE; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; NEPHRITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL ARTERY; SYMPATHECTOMY; VASOMOTOR SYSTEM;

EID: 84901486375     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-051812-145353     Document Type: Review

References (86)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. 2009. Heart disease and stroke statistics-2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 119:480-86
2. Kearney PM, Whelton M, Reynolds K, et al. 2005. Global burden of hypertension: analysis of worldwide data. Lancet 365:217-23 (Pubitemid 40138015)
3. Kannel WB. 1996. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275:1571-76 (Pubitemid 26154243)
4. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al. 2000. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N. Engl. J. Med. 342(1):1-8
5. Lewington S, Clarke R, Qizilbash N, et al. 2002. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349):1903-13 (Pubitemid 35472129)
6. Turnbull F, Neal B, Ninomiya T, et al. 2008. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 336(7653):1121-23 (Pubitemid 351731743)
7. Cutler JA, Sorlie PD, Wolz M, et al. 2008. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 52:818-27
8. Wolf-Maier K, Cooper RS, Kramer H, et al. 2004. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43:10-17 (Pubitemid 38031904)
9. Van Wijk BL, Klungel OH, Heerdink ER, et al. 2005. Rate and determinants of 10-year persistence with antihypertensive drugs. J. Hypertens. 23(11):2101-7 (Pubitemid 41830407)
10. Okonofua EC, Simpson KN, Jesri A, et al. 2006. Therapeutic inertia is an impediment to achieving the Healthy People 2010 Blood Pressure Control Goals. Hypertension 47:345-51 (Pubitemid 43740273)
11. Calhoun DA, Jones D, Textor S, et al. 2008. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association professional education committee of the Council for High Blood Pressure Research. Circulation 117:e510-26
12. Persell SD. 2011. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 57:1076-80
13. Sobotka PA, Mahfoud F, Schlaich MP, et al. 2011. Sympatho-renal axis in chronic disease. Clin. Res. Cardiol. 100(12):1049-57
14. Zanchetti AS. 1977. Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation 56(5):691-98 (Pubitemid 8235170)
15. Bell-Reuss E, Trevino DL, Gottschalk CW. 1976. Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J. Clin. Investig. 57(4):1104-7
16. Kirchheim H, EhmkeH, Persson P. 1989. Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin. Wochenschr. 67(17):858-64 (Pubitemid 19208123)
17. Kon V. 1989. Neural control of renal circulation. Miner. Electrolyte Metab. 15(1-2):33-43 (Pubitemid 19013523)
18. DiBona GF. 2005. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289:R633-41
19. Schlaich MP, Krum H, Sobotka PA, Esler MD. 2011. Renal denervation and hypertension. Am. J. Hypertens. 24:635-42
20. DiBona GF, Kopp UC. 1997. Neural control of renal function. Physiol. Rev. 77:75-197
21. EslerM, JenningsG, Lambert G. 1989. Noradrenaline release and the pathophysiology of primary human hypertension. Am. J. Hypertens. 2(3 Part 2):140S-46S
22. Converse RL Jr, Jacobsen TN, Toto RD, et al. 1992. Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 327:1912-18 (Pubitemid 23006966)
23. Schlaich MP, Lambert E, Kaye DM, et al. 2004. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 43:169-75 (Pubitemid 38174169)
24. Campese VM. 1997. Neurogenic factors and hypertension in chronic renal failure. J. Nephrol. 10(4):184- 87 (Pubitemid 27333193)
25. VitoMC, Ella K. 1995. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25:878-82
26. Campese VM, Kogosov E, Koss M. 1995. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am. J. Kidney Dis. 26(5):861-65
27. Cohen SL. 1973. Hypertension in renal transplant recipients: role of bilateral nephrectomy. BMJ 3(5871):78-81
28. McHugh MI, Tanboga H, Marcen R, et al. 1980. Hypertension following renal transplantation: the role of the host's kidney. Q. J. Med. 49:395-403 (Pubitemid 11210091)
29. Hausberg M, Kosch M, Harmelink P, et al. 2002. Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974-79 (Pubitemid 35176304)
30. Abramczyk P, Zwolinska A, Oficjalski P, et al. 1999. Kidney denervation combined with elimination of adrenal-renal portal circulation prevents the development of hypertension in spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 26(1):32-34
31. Alexander BT, Hendon AE, Ferril G, et al. 2005. Renal denervation abolishes hypertension in low-birthweight offspring from pregnant rats with reduced uterine perfusion. Hypertension 45(4):754-58 (Pubitemid 40418377)
32. Kassab S, Kato T, Wilkins FC, et al. 1995. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 25(4 Part 2):893-97
33. Smithwick RH, Thompson JE. 1953. Splanchnicectomy for essential hypertension: results in 1, 266 cases. JAMA 152(16):1501-4
34. Leishman WD. 1959. Hypertension-treated and untreated. BMJ. 1(5134):1361-68
35. Newcombe CP, Shucksmith HS, SuffernWS. 1959. Sympathectomy for hypertension: follow-up of 212 patients. BMJ. 1(5115):142-44
36. Seldinger SI. 1953. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta Radiol. 39(5):368-76
37. Schlaich MP, HeringD, Sobotka PA, et al. 2012. Renal denervation in human hypertension: mechanisms, current findings, and future prospects. Curr. Hypertens. Rep. 14(3):247-53
38. KrumH, Schlaich M, Whitbourn R, et al. 2009. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275-81
39. Schlaich MP, Sobotka PA, Krum H, et al. 2009. Renal sympathetic-nerve ablation for uncontrolled hypertension. N. Engl. J. Med. 361(9):932-34
40. Symplicity HTN-2 Investig., Esler MD, Krum H, et al. 2010. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SymplicityHTN-2 Trial): a randomised controlled trial. Lancet 376:1903-9
41. Landsberger HA. 1958. Hawthorne Revisited: Management and the Worker, Its Critics, and Developments in Human Relations in Industry. Ithaca, NY: N.Y. State School Ind. Labor Relat., Cornell Univ.
42. Levy D, GarrisonRJ, Savage DD, et al. 1990. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322:1561-66 (Pubitemid 20176696)
43. Bombelli M, Facchetti R, Carugo S, et al. 2009. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J. Hypertens. 27(12):2458-64
44. Pierdomenico SD, Cuccurullo F. 2010. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am. J. Hypertens. 23(8):876-81
45. Brandt MC, Mahfoud F, Reda S, et al. 2012. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J. Am. Coll. Cardiol. 59(10):901-9
46. DiBona GF. 1987. Renal innervation and denervation: lessons from renal transplantation reconsidered. Artif. Organs 11(6):457-62 (Pubitemid 18002359)
47. Symplicity HTN-1 Investig. 2011. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57(5):911-17
48. Arrowood JA, Goudreau E, Minisi AJ, et al. 1995. Evidence against reinnervation of cardiac vagal afferents after human orthotopic cardiac transplantation. Circulation 92(3):402-8
49. Kandzari DE, Bhatt DL, Sobotka PA, et al. 2012. Catheter-based renal denervation for resistant hypertension: rationale and design of the Symplicity HTN-3 trial. Clin. Cardiol. 35(9):528-35
50. ALLHAT Off. Coord. ALLHAT Collab. Res. Group. 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288(23):2981-97
51. Rippy MK, Zarins D, Barman NC, et al. 2011. Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin. Res. Cardiol. 100(12):1095-101
52. Mabin T, Sapoval M, Cabane V, et al. 2012. First experience with endovascular ultrasound renal denervation for treatment of resistant hypertension. EuroIntervention 8(1):57-61
53. Chapman N, Dobson J, Wilson S, et al. 2007. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49:839-45 (Pubitemid 351664214)
54. V'aclav'ik J, Sedl'ak R, Plachy M, et al. 2011. Addition of spironolactone in patientswith resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 57(6):1069- 75
55. Schmieder RE, Redon J, Grassi G, et al. 2012. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J. Hypertens. 30(5):837-41
56. Hering D, Mahfoud F, Walton AS, et al. 2012. Renal denervation in moderate to severe CKD. J. Am. Soc. Nephrol. 23(7):1250-57
57. Pontremoli R, Viazzi F, Martinoli C, et al. 1999. Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrol. Dial. Transplant. 14(2):360-65 (Pubitemid 29062791)
58. Mahfoud F, Cremers B, Janker J, et al. 2012. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 60:419-24
59. Schlaich MP, Socratous F, Hennebry S, et al. 2009. Sympathetic activation in chronic renal failure. J. Am. Soc. Nephrol. 20(5):933-39
60. Amann K, Rump LC, Simonaviciene A, et al. 2000. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J. Am. Soc. Nephrol. 11(8):1469-78 (Pubitemid 30483463)
61. Vonend O, Marsalek P, Russ H, et al. 2003. Moxonidine treatment of hypertensive patients with advanced renal failure. J. Hypertens. 21(9):1709-17 (Pubitemid 37076355)
62. Veelken R, Vogel EM, Hilgers K, et al. 2008. Autonomic renal denervation ameliorates experimental glomerulonephritis. J. Am. Soc. Nephrol. 19(7):1371-78
63. Bock JS, Gottlieb SS. 2010. Cardiorenal syndrome: new perspectives. Circulation 121:2592-600
64. Hasking GJ, EslerMD, Jennings GL, et al. 1986. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73(4):615-21 (Pubitemid 16081418)
65. Cohn JN, Levine TB, Olivari MT, et al. 1984. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311:819-23 (Pubitemid 14035089)
66. Hillege HL, Girbes AR, de Kam PJ, et al. 2000. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102:203-10 (Pubitemid 30451778)
67. Jessup M, Abraham WT, Casey DE, et al. 2009. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53(15):e1-90
68. Cohn JN, Pfeffer MA, Rouleau J, et al. 2003. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur. J. Heart Fail. 5(5):659-67 (Pubitemid 38043972)
69. Sobotka PA, KrumH, Böhm M, et al. 2012. The role of renal denervation in the treatment of heart failure. Curr. Cardiol. Rep. 14(3):285-92
70. West RL, Hernandez AF, O'ConnorCM, et al. 2010.A review of dyspnea in acute heart failure syndromes. Am. Heart J. 160(2):209-14
71. Pocock SJ, WangD, Pfeffer MA, et al. 2006. Predictors ofmortality and morbidity in patients with chronic heart failure. Eur. Heart J. 27:65-75 (Pubitemid 41785934)
72. Flannery G, Gehrig-Mills R, Billah B, et al. 2008. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am. J. Cardiol. 101:865-69
73. Swedberg K, Komajda M, Böhm M, et al. 2010. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875-85
74. Tomaselli GF, Zipes DP. 2004. What causes sudden death in heart failure? Circ. Res. 95(8):754-63 (Pubitemid 39390577)
75. Del Pace S, Parodi G, Bellandi B, et al. 2011. Anxiety trait in patients with stress-induced cardiomyopathy: a case-control study. Clin. Res. Cardiol. 100(6):523-29
76. KomajdaM, Follath F, Swedberg K, et al. 2003. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur. Heart J. 24:464-74 (Pubitemid 36286188)
77. Masuo K, Mikami H, Ogihara T, et al. 1997. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, non-obese Japanese population. Am. J. Hypertens. 10:77-83 (Pubitemid 27038975)
78. Mancia G, Bousquet P, Elghozi JL, et al. 2007. The sympathetic nervous system and the metabolic syndrome. J. Hypertens. 25:909-20 (Pubitemid 46573105)
79. Lima NK, Abbasi F, Lamendola C, et al. 2009. Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am. J. Hypertens. 22:106-11
80. Mahfoud F, Schlaich M, Kindermann I, et al. 2011. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123(18):1940-46
81. Logan AG, Perlikowski SM, Mente A, et al. 2001. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J. Hypertens. 19:2271-77 (Pubitemid 33135251)
82. Somers VK, White DP, Amin R, et al. 2008. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing, in collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 118:1080-111
83. Grassi G, Facchini A, Trevano FQ, et al. 2005. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 46(2):321-25 (Pubitemid 41099164)
84. Witkowski A, Prejbisz A, Florczak E, et al. 2011. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58(4):559-65
85. Tsioufis C, Papademetriou V, Dimitriadis K, et al. 2012. Catheter-based renal sympathetic denervation exerts acute and chronic effects on renal hemodynamics in swine. Int. J. Cardiol. 168(2):987-92
86. Katholi RE, Whitlow PL, Hageman GR, et al. 1984. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J. Hypertens. 2(4):349-59 (Pubitemid 14004193)